Research News and Research

RSS

Discovery: VPS4A enzyme plays a key role in release of HIV particles

Human Immunodeficiency Virus - which causes AIDS - invades human immune cells and causes them to produce new copies of the virus, which can then infect new cells.

11 Mar 2011

House bill introduced to allow individuals to apply for health law waivers

The measure, introduced by Rep. Mike Rogers, R-Mich., would allow consumers the same exemption process being exercised by some employers and unions. Meanwhile, House Oversight Committee Chairman Darrell Issa, R-Calif., has raised questions about waivers granted to "mini-med" plans.

11 Mar 2011

Defunding strategy takes aim at health law's mandatory spending provisions

The House Energy and Commerce Health Subcommittee held a hearing yesterday to begin the process of marking up legislation to remove certain parts of health law funding.

11 Mar 2011

OncoVista plans to advance reduced-toxicity targeted cancer treatments

OncoVista Innovative Therapies, Inc., reported in a letter to shareholders that it is moving forward on its business plan to develop targeted, safer and more efficacious cancer treatments with reduced or no toxicity.

11 Mar 2011

Walgreens sells Pharmacy Benefits Manager to Catalyst Health Solutions

Catalyst Health Solutions Inc said it will buy Walgreen Co's pharmacy benefits management unit for about $525 million in cash, a deal that might spur more consolidation before big generic drug launches that could boost the business.

11 Mar 2011

Canadian House of Commons passes bill that could ease access to generic drugs in developing countries

Canadian lawmakers in the country's House of Commons on Wednesday "approved a bill aiming to ease the process that lets generic drug manufacturers produce patented medicines for export to poor nations at cheaper prices in a move the pharmaceutical industry says could undermine intellectual property rights," Bloomberg reports.

11 Mar 2011

Researchers concerned about use of mercury-based compound in inactivated flu vaccines

As the United Nations, the European Commission, and the United States Food and Drug Administration evaluate the health and environmental risks associated with mercury, a known neurotoxin, carcinogen, mutagen, teratogen, and immune-system disruptor, new research continues to fuel concerns about Thimerosal, a mercury-based compound used as a preservative in inactivated flu vaccines.

11 Mar 2011

Murad launches new powerhouse anti-aging treatment product

Murad, Inc. has announced the launch of Complete Reform with Glyco Firming Complex, the latest powerhouse anti-aging treatment product in the company's award-winning Age Reform line.

11 Mar 2011

Australian, U.S. Department of VA to collaborate on new military deployment research project

The U.S. Department of Veterans Affairs will collaborate with the Australian Department of Veterans Affairs on a new research effort focused on investigating the impact of recent conflicts on the health of returning Servicemembers.

11 Mar 2011

Sec. Clinton launches global partnership to improve maternal, child health

Secretary of State Hillary Rodham Clinton on Wednesday announced the launch of a global partnership between USAID, the Bill & Melinda Gates Foundation, the non-profit Grand Challenges Canada, the World Bank, and the government of Norway to reduce the number of deaths among mothers and infants in developing countries, the Globe and Mail reports.

11 Mar 2011

Experts ponder questions regarding law's 'essential benefits' package

When it comes to health insurance, deciding what is an essential benefit — and what isn't — is a political and medical minefield, with far-reaching consequences.

11 Mar 2011

Researchers uncover new disease mechanism in patients with CGD

Infection researchers at Umeå University have uncovered a new disease mechanism in patients with Chronic Granulomatous Disease in an international clinical collaboration with the Children's Hospital in Zurich.

11 Mar 2011

NIH awards Avaxia Phase I SBIR grant to develop novel antibody therapeutic for celiac disease

Avaxia Biologics, Inc., a privately-held biotech company using its proprietary platform technology to develop orally-active antibody therapeutics for the treatment of gastrointestinal diseases, announced today that it has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health (NIH), to support the development of a novel antibody therapeutic for celiac disease.

11 Mar 2011

GSK announces new NovaMin-containing dental formulation for sensitive teeth

This year, for the first time, millions of Americans will be protecting their sensitive teeth with NovaMin in everyday dental products. Co-inventor Gary Hack, DDS, couldn't be happier.

11 Mar 2011

Medicare fraud costs taxpayers big money

Medicare could wrench as much as $70 billion a year in savings by cracking down on fraud, experts told Congress this week.

11 Mar 2011

Females willing to work more harder for cocaine than males

It seems that women become addicted to cocaine more easily than men and find it harder to give up. New research published in BioMed Central's open access journal Biology of Sex Differences reinforces this position by showing that the motivation of female rats to work for cocaine is much higher than males.

11 Mar 2011

Harvard, Oxford Nanopore enter exclusive agreement for graphene DNA sequencing

Oxford Nanopore Technologies Ltd today announced an exclusive agreement with Harvard University's Office of Technology Development for the development of graphene for DNA sequencing.

From Oxford Nanopore Technologies 11 Mar 2011

Majority of Americans support government involvement in distribution of genetic test

A report released by Cogent Research reveals that a majority of Americans support government involvement in the distribution of direct-to-consumer genomics-based tests.

11 Mar 2011

New North American survey highlights impact of more complex clinical trials

A new North American survey of 500+ clinical research site professionals documents the impact of more kinds of, and more complex, clinical trials. The survey focused on 3-year trial trends and found key challenges in subject recruitment/retention and tracking and reporting data.

11 Mar 2011